Fig. 6

CeNP-PEG rebalanced the proinflammatory microenvironment in the colitis models. A Representative CTE images of colitis models after treatment with PBS, 3% DSS and 3% DSS + CeNP-PEG. Segmental bowel wall thickening with mucosal enhancement in DSS-induced colitis models is indicated by red arrows. The alleviation of symtoms after CeNP-PEG treatment is indicated by yellow arrows. B The bowel wall thickness was measured by CT (PBS and DSS + CeNP-PEG groups n = 3, DSS group n = 4). C Musocal enhancement ratio (the ratio of venous stage enhancement to plain scan) was measured by CT (PBS and DSS + CeNP-PEG groups n = 3, DSS group n = 4). D PET/CT images of intestinal inflammatory tissues visualized by the radiotracer [¹⁸F]-DPA-714 on day 9 after CeNP-PEG treatment. Uptake in the small intestines (red arrow) and distal colon (yellow arrow) in colitis models was attenuated (red and yellow arrows) after CeNP-PEG treatment. E Quantification of [¹⁸F]-DPA-714 radioactivity in the colon (PBS and DSS + CeNP-PEG groups n = 3, DSS group n = 4). F The mRNA levels of TNF-α, IL-6, IL-1β, and IFN-γ in colonic tissues on day 9 (n = 3). G The serum levels of TNF-α, IL-6, IL-1β, and IFN-γ in colitis model mice on day 9 (n = 3). The data are presented as the mean ± SD. One-way ANOVA was used for statistical analysis